Cargando…

Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity

Dengue is one of the most frequently transmitted mosquito-borne diseases in the world, which creates a significant public health concern globally, especially in tropical and subtropical countries. It is estimated that more than 390 million people are infected with dengue virus each year and around 9...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izmirly, Abdullah M., Alturki, Sana O., Alturki, Sawsan O., Connors, Jennifer, Haddad, Elias K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325873/ https://www.ncbi.nlm.nih.gov/pubmed/32655548 http://dx.doi.org/10.3389/fimmu.2020.01055

Ejemplares similares

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
por: Alturki, Sana O., et al.
Publicado: (2020)

Pre-vaccination frequency of circulatory Tfh is associated with robust immune response to TV003 dengue vaccine
por: Izmirly, Abdullah M., et al.
Publicado: (2022)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
por: Henze, Larissa, et al.
Publicado: (2023)

The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains
por: Nienen, Mikalai, et al.
Publicado: (2019)

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
por: Wang, Jin, et al.
Publicado: (2021)

Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development
por: Elong Ngono, Annie, et al.
Publicado: (2019)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children
por: Li, Nina, et al.
Publicado: (2022)

Immunoinformatics Aided Design and In-Vivo Validation of a Cross-Reactive Peptide Based Multi-Epitope Vaccine Targeting Multiple Serotypes of Dengue Virus
por: Kaushik, Vikas, et al.
Publicado: (2022)

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement
por: Sarker, Animesh, et al.
Publicado: (2023)

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
por: Tejedor Vaquero, Sonia, et al.
Publicado: (2021)

Selective contralateral balloon occlusion for successful opening of a persistently collapsed lung in congenital lobar emphysema
por: Alwadai, Abdullah, et al.
Publicado: (2006)

The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
por: Murray, Sam M., et al.
Publicado: (2022)

The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
por: Callender, Lauren A., et al.
Publicado: (2020)

Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant
por: McQuiston, Alexander, et al.
Publicado: (2021)

The Challenges Imposed by Dengue, Zika, and Chikungunya to Brazil
por: Zanotto, Paolo Marinho de Andrade, et al.
Publicado: (2018)

Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity
por: Desikan, Rajat, et al.
Publicado: (2022)

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine
por: Lima, Noemia S., et al.
Publicado: (2021)

Cross-Reactivity and Anti-viral Function of Dengue Capsid and NS3-Specific Memory T Cells Toward Zika Virus
por: Lim, Mei Qiu, et al.
Publicado: (2018)

Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections
por: Nguyen, Hung D., et al.
Publicado: (2021)

Cross-Reactivity of TCR Repertoire: Current Concepts, Challenges, and Implication for Allotransplantation
por: Degauque, Nicolas, et al.
Publicado: (2016)

Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens
por: Bettencourt, Paulo
Publicado: (2020)

Unusual Case of a 13-Year-Old Male with Blount's Disease Who was Unable to Walk: A Prevention Lesson
por: AlTurki, Yousef Abdullah
Publicado: (2016)

Dengue Serotype Cross-Reactive, Anti-E Protein Antibodies Confound Specific Immune Memory for 1 Year after Infection
por: Toh, Ying Xiu, et al.
Publicado: (2014)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Rethinking detection of pre-existing and intervening Plasmodium infections in malaria clinical trials
por: Owalla, Tonny J., et al.
Publicado: (2022)

The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
por: Gouttefangeas, Cécile, et al.
Publicado: (2023)

Is there a link between pre-existing antibodies acquired due to childhood vaccinations or past infections and COVID-19? A case control study
por: Sumbul, Bilge, et al.
Publicado: (2021)

Recent Developments in Recombinant Protein–Based Dengue Vaccines
por: Tripathi, Nagesh K., et al.
Publicado: (2018)

Anti-dengue Vaccines: From Development to Clinical Trials
por: Pinheiro-Michelsen, Josilene Ramos, et al.
Publicado: (2020)

Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design
por: Subramaniam, Krishanthi S., et al.
Publicado: (2020)

Aging alters immune responses to vaccines
por: Connors, Jennifer, et al.
Publicado: (2021)

Cross-Reactivity of Rapid Salmonella Typhi IgM Immunoassay in Dengue Fever Without Co-Existing Infection
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection
por: Yuen, Rachel R., et al.
Publicado: (2021)

The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trial
por: Low, Jenny G, et al.
Publicado: (2015)

Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020
por: de Oliveira-Filho, Edmilson F., et al.
Publicado: (2022)

Comparison of Neutralizing Dengue Virus B Cell Epitopes and Protective T Cell Epitopes With Those in Three Main Dengue Virus Vaccines
por: Pinheiro, Josilene Ramos, et al.
Publicado: (2021)

Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis
por: Cheng, Yi-Ling, et al.
Publicado: (2022)

Isolating Human Monoclonal Antibodies Against Adeno-Associated Virus From Donors With Pre-existing Immunity
por: Giles, April R., et al.
Publicado: (2020)

BCG Vaccine Derived Peptides Induce SARS-CoV-2 T Cell Cross-Reactivity
por: Eggenhuizen, Peter J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ftpu4ess03ujssiv6kens0enmk